- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 1, 2023
Highlights
- Market Cap
- $14.84M
- Enterprise Value
- -$4.46M
- EPS (TTM)
- -$1.06
- Gross Profit (TTM)
- -$189.00K
- EBITDA (TTM)
- -$62.18M
- Year Range
- $0.11 - $4.20
- ROA (TTM)
- -21.59%
- ROE (TTM)
- -26.02%
- Avg. Volume (1M)
- 2K
- Avg. Volume Value (1M)
- $763.55
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ENGNW Performance Chart
enGene Holdings Inc. Warrants (ENGNW) is down 90.2% since the beginning of the year. At $0 per share, ENGNW is trading 93.1% below its 52-week high of $4.
Loading charts...
Compare this symbol against anything
Returns By Period
enGene Holdings Inc. Warrants (ENGNW) has returned -90.21% so far this year and -60.84% over the past 12 months.
enGene Holdings Inc. Warrants
- 1D
- -17.18%
- 1M
- -0.03%
- 6M
- -89.46%
- YTD
- -90.21%
- 1Y
- -60.84%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -29.27%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ENGNW Monthly Returns History
Based on dividend-adjusted daily data since Nov 1, 2023, ENGNW's average daily return is +0.93%, while the average monthly return is +12.07%. At this rate, an investment would double in approximately 0.5 years.
Historically, 45% of months were positive and 55% were negative. The best month was Feb 2024 with a return of +334.6%, while the worst month was May 2026 at -85.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, ENGNW closed higher 34% of trading days. The best single day was Oct 15, 2025 with a return of +215.7%, while the worst single day was May 7, 2026 at -90.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.09% | 14.55% | -19.68% | -20.95% | -85.50% | 0.00% | -0.03% | -90.21% | |||||
| 2025 | 12.65% | -24.21% | -16.61% | 36.58% | -2.44% | 2.50% | 10.98% | -25.27% | 4.41% | 180.28% | 38.56% | 7.35% | 251.00% |
| 2024 | -4.71% | 334.57% | 47.73% | -22.12% | -39.51% | -51.43% | 13.45% | -18.52% | 90.91% | -24.29% | -10.69% | -40.61% | -0.79% |
| 2023 | -13.33% | 30.77% | 13.33% |
Benchmark Metrics
enGene Holdings Inc. Warrants has an annualized alpha of 642.50%, beta of 1.53, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since November 01, 2023.
- This stock participated in 327.01% of S&P 500 Index downside but only 27.37% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 642.50%
- Beta
- 1.53
- R²
- 0.01
- Upside Capture
- 27.37%
- Downside Capture
- 327.01%
Return for Risk
Risk / Return Rank
ENGNW ranks 46 for risk / return — above 46% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for enGene Holdings Inc. Warrants (ENGNW) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ENGNW | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.65 | ||
| Sortino ratioReturn per unit of downside risk | +0.12 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.25 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | -0.70 | 2.00 | -2.71 |
| Martin ratioReturn relative to average drawdown | -1.30 | 8.49 | -9.79 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the enGene Holdings Inc. Warrants. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the enGene Holdings Inc. Warrants was 98.12%, occurring on May 8, 2026. The portfolio has not yet recovered.
The current enGene Holdings Inc. Warrants drawdown is 95.46%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.12%May 2026 | 2y 1mo | — | 2y 4moMar 2024 - now | — |
-50.00%Nov 2023 | 4d | 1mo 28d | 2mo 2dNov 2023 - Jan 2024 | — |
-25.69%Jan 2024 | 26d | 5d | 1mo 1dJan 2024 - Feb 2024 | — |
-19.82%Feb 2024 | 0s | 6d | 6dFeb 2024 - Feb 2024 | — |
-11.34%Feb 2024 | 2d | 1d | 3dFeb 2024 - Mar 2024 | — |
Drawdown Indicators
| ENGNW | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.12% | -56.78% | -41.34% |
Max Drawdown (1Y)Largest decline over 1 year | -97.14% | -9.10% | -88.04% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -95.46% | -1.58% | -93.88% |
Average DrawdownAverage peak-to-trough decline | -66.28% | -10.70% | -55.58% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 53.04% | 2.14% | +50.90% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of enGene Holdings Inc. Warrants over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how enGene Holdings Inc. Warrants is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ENGNW in comparison with other companies in the Biotechnology industry. Currently, ENGNW has a P/B value of 0.1. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ENGNW
Add enGene Holdings Inc. Warrants to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ENGNW